ONEST (Observers Needed to Evaluate Subjective Tests) Analysis of Stromal Tumour-Infiltrating Lymphocytes (sTILs) in Breast Cancer and Its Limitations.
European Working Group for Breast Screening Pathology
ONEST
TILs
breast cancer
international immuno-oncology biomarker working group
observers needed to evaluate subjective tests
reproducibility
sTILs
triple-negative
tumour-infiltrating lymphocytes
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Feb 2023
14 Feb 2023
Historique:
received:
20
01
2023
revised:
04
02
2023
accepted:
09
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Tumour-infiltrating lymphocytes (TILs) reflect antitumour immunity. Their evaluation of histopathology specimens is influenced by several factors and is subject to issues of reproducibility. ONEST (Observers Needed to Evaluate Subjective Tests) helps in determining the number of observers that would be sufficient for the reliable estimation of inter-observer agreement of TIL categorisation. This has not been explored previously in relation to TILs. ONEST analyses, using an open-source software developed by the first author, were performed on TIL quantification in breast cancers taken from two previous studies. These were one reproducibility study involving 49 breast cancers, 23 in the first circulation and 14 pathologists in the second circulation, and one study involving 100 cases and 9 pathologists. In addition to the estimates of the number of observers required, other factors influencing the results of ONEST were examined. The analyses reveal that between six and nine observers (range 2-11) are most commonly needed to give a robust estimate of reproducibility. In addition, the number and experience of observers, the distribution of values around or away from the extremes, and outliers in the classification also influence the results. Due to the simplicity and the potentially relevant information it may give, we propose ONEST to be a part of new reproducibility analyses.
Identifiants
pubmed: 36831541
pii: cancers15041199
doi: 10.3390/cancers15041199
pmc: PMC9954449
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Mod Pathol. 2020 Sep;33(9):1746-1752
pubmed: 32300181
Pathol Oncol Res. 2022 Jun 27;28:1610373
pubmed: 35845921
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
NPJ Breast Cancer. 2021 Dec 1;7(1):150
pubmed: 34853355
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Am J Clin Pathol. 2018 Oct 01;150(5):441-450
pubmed: 30052720
J Clin Oncol. 2019 Mar 1;37(7):559-569
pubmed: 30650045
Mod Pathol. 2016 Oct;29(10):1155-64
pubmed: 27363491
Indian J Pathol Microbiol. 2018 Apr-Jun;61(2):181-186
pubmed: 29676353
Ann Diagn Pathol. 2018 Aug;35:77-79
pubmed: 29886396
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Cancers (Basel). 2021 Aug 31;13(17):
pubmed: 34503219
Acta Oncol. 2018 Jan;57(1):90-94
pubmed: 29168428
Ann Surg Oncol. 2016 Jul;23(7):2242-8
pubmed: 26965699
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Mod Pathol. 2021 Dec;34(12):2130-2140
pubmed: 34218258
Virchows Arch. 2021 Dec;479(6):1101-1109
pubmed: 34415429
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25
pubmed: 29024776
Ann Oncol. 2014 Aug;25(8):1544-50
pubmed: 24608200
Mod Pathol. 2017 Sep;30(9):1204-1212
pubmed: 28621322
Breast Cancer Res Treat. 2018 Aug;171(1):1-9
pubmed: 29774470
J Immunother Cancer. 2016 Oct 18;4:59
pubmed: 27777769
Pathol Res Pract. 2022 Jan;229:153718
pubmed: 34920295
NPJ Breast Cancer. 2020 May 12;6:17
pubmed: 32411819
Anticancer Res. 2021 Apr;41(4):2133-2140
pubmed: 33813424
Magy Onkol. 2020 Dec 14;64(4):301-328
pubmed: 33313608
J Natl Cancer Inst. 2019 Aug 1;111(8):867-871
pubmed: 30888406
Virchows Arch. 2022 Jan;480(1):147-162
pubmed: 35043236
Pol J Pathol. 2019;70(2):139-143
pubmed: 31556565